Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420482 · ClinicalTrials.gov registry record · Phase 2
Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
A Phase 2 study of Hepatic Encephalopathy, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03420482 is a Phase 2 study of Hepatic Encephalopathy that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 174-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03420482, a Phase 2 study of Hepatic Encephalopathy, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A common complication of advanced liver disease is a condition called hepatic encephalopathy, which leads to confusion. The current treatment options cause side effects, are costly, and do not always work. An abnormal population of bacteria in the intestines may be causing this condition, and transplanting bacteria from the colon of a healthy person may treat it. In this research study, the investigators will first find two healthy stool donors whose stool donation improves the gut bacteria of patients with advanced liver disease and helps them think more clearly. Then, in a randomized controlled trial, the investigators will compare the ability of stool donation from these two best donors versus a placebo to improve the neurological function of patients with advanced liver disease. If the investigators find the expected results, there will be a new effective therapy for patients with advanced liver disease and the very troublesome complication of hepatic encephalopathy.
Conditions Studied
Interventions
- DRUG Placebo oral capsule
- DRUG Fecal Microbiota Transplant (FMT) oral capsules
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03420482
The ClinicalTrials.gov registry entry for NCT03420482 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 12 other Hepatic Encephalopathy trials with a reported enrollment target (83% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Encephalopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsule is the first listed.
NCT03420482 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03420482 about?
NCT03420482 is a clinical study titled "Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy". A common complication of advanced liver disease is a condition called hepatic encephalopathy, which leads to confusion. The current treatment options cause side effects, are costly, and do not always work. An abnormal population of bacteria in the intestines may be causing this condition, and transp...
What is the current status of trial NCT03420482?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-04-01. Estimated completion is 2027-01-31.
What conditions does trial NCT03420482 study?
This clinical trial studies the following conditions: Hepatic Encephalopathy.
What interventions are being tested in trial NCT03420482?
The interventions under investigation include: Placebo oral capsule (DRUG), Fecal Microbiota Transplant (FMT) oral capsules (DRUG).
Who is sponsoring clinical trial NCT03420482?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03420482 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Encephalopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
TReatment for ImmUne Mediated PathopHysiology
RECRUITING · Phase 2
-
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
COMPLETED · Phase 2
-
Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
RECRUITING · NA
-
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
RECRUITING · NA
-
Affect of Melatonin on Sleep and Cognition in Cirrhosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.